Previous 10 | Next 10 |
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE...
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai , M.D., to its board of directors. D...
Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale PR Newswire -- Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million -- ...
Summary Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. The price response to these updates hasn't held into the final stages of the year, however. There are multiple inflectio...
Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...
Blueprint Medicines ( NASDAQ: BPMC ) reported long term updated of Ayvakit from the PATHFINDER and EXPLORER trials in patients with advanced systemic mastocytosis (SM) and part of 1 of the HARBOR study of elenestinib. Ayvakit is approved in the US. to treat ...
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAM...
Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acce...
Oppenheimer downgraded Blueprint Medicines Corporation ( NASDAQ: BPMC ) to Perform from Outperform at Oppenheimer on Wednesday, noting challenges in the rollout of the biotech's cancer therapy Ayvakit. In January 2020, the FDA approved Ayvakit for certain patients with met...
Blueprint Medicines press release ( NASDAQ: BPMC ): Q3 GAAP EPS of -$2.23 beats by $0.28 . Revenue of $65.97M (+172.7% Y/Y) beats by $22.09M . GUIDANCE: Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for ful...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective March 1, 2024, the C...
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...